Lexitas Acquired by NovaQuest to Support Continued Growth and Capability Expansion

July 19, 2022

Overview

Lexitas Pharma Services has been acquired by NovaQuest Private Equity to support continued growth and capability expansion.

Significance

Lexitas provides clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company’s therapeutic area expertise, relationships with ophthalmic KOLs, and network of high-performing research sites made it an attractive acquisition opportunity for NovaQuest Private Equity, whose philosophy of providing strategic capital to growing clinical trial services providers in niche, specialized therapeutic areas makes them an ideal partner to support Lexitas’ continued growth.

Crosstree’s Role

Crosstree helped Lexitas identify NovaQuest as the ideal strategic partner to accelerate growth through:

  • Synthesizing the company’s unique offering and market position into a clear and compelling value proposition
  • Evaluating a targeted slate of potential financial and strategic partners with relevant industry expertise and compatible strategic vision
  • Tailoring a capital structure to deliver exceptional returns to early investors and support future value creation